Samad M, Mahboob E, Mansoor H
Blood Res. 2022; 57(2):95-100.
PMID: 35620905
PMC: 9242828.
DOI: 10.5045/br.2022.2021173.
Mayerhofer C, Niemeyer C, Flotho C
J Clin Med. 2021; 10(14).
PMID: 34300250
PMC: 8305558.
DOI: 10.3390/jcm10143084.
Klco J, Mullighan C
Nat Rev Cancer. 2020; 21(2):122-137.
PMID: 33328584
PMC: 8404376.
DOI: 10.1038/s41568-020-00315-z.
Patnaik M, Lasho T
Hematology Am Soc Hematol Educ Program. 2020; 2020(1):450-459.
PMID: 33275756
PMC: 7727543.
DOI: 10.1182/hematology.2020000130.
Schonung M, Meyer J, Nollke P, Olshen A, Hartmann M, Murakami N
Clin Cancer Res. 2020; 27(1):158-168.
PMID: 33139265
PMC: 7785676.
DOI: 10.1158/1078-0432.CCR-20-3184.
PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
Miao Y, Li B, Ding L, Zhu H, Luo C, Wang J
Eur J Pediatr. 2019; 179(3):463-472.
PMID: 31807902
PMC: 7028800.
DOI: 10.1007/s00431-019-03468-8.
Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
Pearson S, Guo B, Pierce A, Azadbakht N, Brazzatti J, Patassini S
J Proteome Res. 2019; 19(1):194-203.
PMID: 31657576
PMC: 6942217.
DOI: 10.1021/acs.jproteome.9b00495.
Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Hashmi S, Punia J, Marcogliese A, Gaikwad A, Fisher K, Roy A
Pediatr Blood Cancer. 2019; 66(10):e27905.
PMID: 31250550
PMC: 7328527.
DOI: 10.1002/pbc.27905.
Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.
Flotho C
Epigenetics. 2019; 14(3):236-244.
PMID: 30773984
PMC: 6557547.
DOI: 10.1080/15592294.2019.1583039.
Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
Tasian S, Casas J, Posocco D, Gandre-Babbe S, Gagne A, Liang G
Leukemia. 2018; 33(1):181-190.
PMID: 29884903
PMC: 6286697.
DOI: 10.1038/s41375-018-0169-y.
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka D, Witte T, Toth R, Yang J, Wiesenfarth M, Nollke P
Nat Commun. 2017; 8(1):2126.
PMID: 29259247
PMC: 5736667.
DOI: 10.1038/s41467-017-02177-w.
Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of Sixty-five Patients.
Tufekci O, Kocak U, Kaya Z, Yenicesu I, Albayrak C, Albayrak D
Turk J Haematol. 2017; 35(1):27-34.
PMID: 28179213
PMC: 5843771.
DOI: 10.4274/tjh.2017.0021.
CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.
Fluhr S, Boerries M, Busch H, Symeonidi A, Witte T, Lipka D
Clin Epigenetics. 2016; 8:50.
PMID: 27158276
PMC: 4858931.
DOI: 10.1186/s13148-016-0216-3.
Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy.
Muraoka M, Okuma C, Kanamitsu K, Ishida H, Kanazawa Y, Washio K
J Hum Genet. 2016; 61(6):523-6.
PMID: 26911351
DOI: 10.1038/jhg.2016.8.
The genomic landscape of juvenile myelomonocytic leukemia.
Stieglitz E, Taylor-Weiner A, Chang T, Gelston L, Wang Y, Mazor T
Nat Genet. 2015; 47(11):1326-1333.
PMID: 26457647
PMC: 4626387.
DOI: 10.1038/ng.3400.
Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
Tufekci O, Oren H, Demir Yenigurbuz F, Gozmen S, Karapinar T, Irken G
Turk J Haematol. 2015; 32(2):175-9.
PMID: 26316488
PMC: 4451488.
DOI: 10.4274/tjh.2014.0034.
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
Stieglitz E, Troup C, Gelston L, Haliburton J, Chow E, Yu K
Blood. 2014; 125(3):516-24.
PMID: 25395418
PMC: 4296011.
DOI: 10.1182/blood-2014-09-601690.
RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia.
Poetsch A, Lipka D, Witte T, Claus R, Nollke P, Zucknick M
Epigenetics. 2014; 9(9):1252-60.
PMID: 25147919
PMC: 4169017.
DOI: 10.4161/epi.29941.
Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis.
Flex E, Jaiswal M, Pantaleoni F, Martinelli S, Strullu M, Fansa E
Hum Mol Genet. 2014; 23(16):4315-27.
PMID: 24705357
PMC: 4103678.
DOI: 10.1093/hmg/ddu148.
Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N, Doisaki S, Kojima S
Paediatr Drugs. 2012; 14(3):157-63.
PMID: 22480363
DOI: 10.2165/11631360-000000000-00000.
